Skip to content
Life Sciences Series A Founded 2012

Single Technologies

Single Technologies has created 3-D Sequencing, a cube-style DNA sequencing solution that moves beyond traditional flat-surface scaling to three-dimensional architecture. The technology drastically increases the number of DNA sequences that can be read in parallel and naturally unites sequencing with spatial biology. The company's upcoming Theta platform is the world's first 3-D sequencer, enabling massive…

📍 Stockholm, Sweden · Life Sciences Platforms and Tools,

Funding snapshot

Last roundSeries A
Amount$382K
Date1 March 2024
Total raised$8M
Team size33

About

Single Technologies has created 3-D Sequencing, a cube-style DNA sequencing solution that moves beyond traditional flat-surface scaling to three-dimensional architecture. The technology drastically increases the number of DNA sequences that can be read in parallel and naturally unites sequencing with spatial biology. The company's upcoming Theta platform is the world's first 3-D sequencer, enabling massive parallelism in both in situ and solution-based DNA sequencing with unprecedented throughput. The multi-layered structure delivers unparalleled data throughput, and the unique in-cell 3-D sequencing capability allows higher read counts per cell and analysis of more cells in a single run. Single Technologies empowers innovators in gene editing, proteomics, and spatial biology research. Founded in 2012, headquartered in Stockholm, Sweden, The company has raised $7.6M at the Series A stage, backed by investors including KTH Holding, Rothesay, Europa, Almi Invest..

Business model

Genomics > Enabling Technologies > Instrument Systems > Nucleic Acid Analysis > Sequencing,

Life Sciences Platforms and Tools > Instruments > Genomics > Nucleic Acid Sequencing

Institutional investors

KTH Holding Rothesay Europa Almi Invest Jens von Bahr Andreas Ehn

Latest coverage

No articles yet.

Raising like Single Technologies?

Analyze your pitch deck before your next raise.

Analyze My Deck →